Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6862698 | 0.73 | TSHR (0.31) | GAA | |
| SCHEMBL6859448 | 0.71 | EPHX2 (0.39) | EPHX1EPHX2GAAMEN1KMT2A | |
| SCHEMBL6854374 | 0.71 | EPHX1 (0.34) | EPHX1EPHX2GAATHRBCYP2C9 | |
| SCHEMBL5563682 | 0.68 | EPHX2 (0.34) | EPHX1EPHX2SMN1; SMN2LMNAGAA | |
| SCHEMBL160641 | 0.68 | THRB (0.35) | EPHX1EPHX2SMN1; SMN2LMNAGAA | |
| SCHEMBL6861145 | 0.68 | PKM (0.31) | GAA | |
| SCHEMBL6860439 | 0.67 | HSD11B1 (0.46) | EPHX1EPHX2GAAMEN1KMT2A | |
| SCHEMBL31065066 | 0.67 | THRB (0.34) | EPHX1EPHX2SMN1; SMN2LMNAGAA | |
| SCHEMBL31065065 | 0.67 | THRB (0.34) | EPHX1EPHX2SMN1; SMN2LMNAGAA | |
| SCHEMBL6860355 | 0.66 | KMT2A (0.34) | EPHX2SMN1; SMN2LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6794528-B2 | HEAT RESISTANCE, FLAME RETARDERS, STABILIZERS; REACTING DIALCOHOL COMPOUND WITH A PHOSPHYL OXYCHLORIDE COMPOUND | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2004-09-21 | — | — | US | disclosed |
| US-20030109736-A1 | Phosphorus compound | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2003-06-12 | — | — | US | disclosed |
| EP-1277758-A1 | PHOSPHORUS COMPOUND | Daicel Chemical Industries, Ltd. (JP) | 2003-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109736-A1 | Phosphorus compound | NR4A1, POLL, NR0B1 | EPHX1 3912/4885EPHX2 3620/4885SMN1; SMN2 3216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.